Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
CASI - Key Highlights

• U.S. Nasdaq-listed company with China operations and dedicated cross-border management team with deep knowledge of global drug development, tech transfer & commercialization in both China & the U.S.

• Launched first product EVOMELA® in China – August 2019

• Opportunistic business model enables us to leverage recent NMPA reforms and continuously explore & expand drug development in areas of unmet medical need and commercial opportunity.

• Robust pipeline in hematological malignancies and solid tumors as initial therapeutic segment; goal to help patients achieve long term disease control

• Active BD to take advantage of scalable platform and in pursuit of pipeline expansion

• State-of-the-art GMP manufacturing facility currently in design stage

• Backed by returning committed investors and fundamental investors

• Over 100 employees in China and U.S., with key employees trained in global operations and with extensive network and expertise in U.S./China clinical, regulatory and commercial execution
Recent Execution in Hematology Oncology Portfolio

**Evomela (melphalan) for Injection**
- **Launched in China for multiple myeloma transplant setting in August 2019**

**CNCT-19 CD19 CAR-T**
- Acquired worldwide rights to commercialize CD19 CAR-T cell therapy in June 2019
  - December 2019 NMPA approval of Phase 1 trial for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
  - December 2019 NMPA approval of Phase 1 trial for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)

**CID-103 anti-CD38 mAb**
- In-licensed exclusive worldwide rights to novel anti-CD38 monoclonal antibody program in April 2019 – targeting multiple myeloma

**Marqibo**
- NMPA approved MARQibo® for Clinical Trial of Investigation in April 2019

**ZEVALIN**
- NMBA approved ZEVALIN® for Clinical Trial of Investigation in March 2019

**Octreotide**
- Acquired China rights to Octreotide in Nov 2019 for neuroendocrine tumors and acromegaly
# CASI Product & Pipeline

## Investigational Innovative Drug Candidate with Global Rights

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>PRE-CLINICAL</th>
<th>IND/IMPD</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CID-103 (Anti-CD 38 mAb)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## China Developed Innovative Cell Therapy with Global Commercial Rights

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
<th>LAUNCH IN CHINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNTC19 (Autologous Anti-CD19 T-cell therapy)</td>
<td>IN-LICENSED</td>
<td>CTA FILING &amp; REVIEW</td>
<td>REGISTRATION TRIAL</td>
<td>NDA FILING &amp; REVIEW</td>
<td>LAUNCH IN CHINA</td>
</tr>
<tr>
<td>Hematological Malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## U.S. FDA-Approved Products in-Licensed for Greater China Region

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
<th>LAUNCH IN CHINA</th>
<th>LAUNCHED AND COMMERCIALLY AVAILABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVOMELA®</td>
<td>IN-LICENSED</td>
<td>CTA FILING &amp; REVIEW</td>
<td>REGISTRATION TRIAL</td>
<td>NDA FILING &amp; REVIEW</td>
<td>LAUNCH IN CHINA</td>
<td>Launched and commercially available in China</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZEVALIN®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin’s Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MARQIBO®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Lymphoblastic Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## EU-Approved Product in-Licensed for China

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
<th>LAUNCH IN CHINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide LAI</td>
<td>IN-LICENSED</td>
<td>CTA FILING &amp; REVIEW</td>
<td>REGISTRATION TRIAL</td>
<td>NDA FILING &amp; REVIEW</td>
<td>LAUNCH IN CHINA</td>
</tr>
<tr>
<td>Symptoms associated with neuroendocrine cancers and acromegaly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EVOMELA® Launched in China for Multiple Myeloma

- Currently only approved melphalan product in China market
- Exclusive greater China rights to Evomela
- HDT + ASCT is 1st line treatment for multiple myeloma even in new agent era
- Provides best choice of preparative regimen
  - Lack of propylene glycol solvent (related to certain adverse events)
- Stable and significantly improves handling for physicians
  - Captisol formulation allows for increased stability when reconstituted for patient administration
- As condition to NMPA approval, CASI will implement a post-marketing study after market launch
- Successfully Launched in August 2019 – initial sales exceeded target forecast
CNCT-19: CD19 CAR-T Cell Therapy

- Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies
- CD19-targeted CAR have demonstrated consistently high antitumor efficacy in children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL)
- CD19 antigen is the most frequently used biomarker in CAR-T cell therapy clinical trials for hematological malignancies
- CASI has exclusive China and worldwide commercial rights
- Clinical trial application approved by NMPA December 2019 for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL);
  - Registration trials expected to initiate in early 2020
- Clinical trial application approved by NMPA December 2019 for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL);
  - Registration trials expected to initiate in early 2020
CID-103: Potential Best in Class Anti-CD38 mAb

- Fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope; engineered to have strong ADCC activity against CD38 malignant cells and to reduce CDC activity with a potential reduction of infusion reactions with observed with existing anti-CD38 treatments
- Encouraging preclinical efficacy & safety profile compared to other anti-CD38 mAbs
- Demonstrates greater ADCC activity over Daratumumab and other anti-CD38 mAbs
- In vivo activity outperforms Daratumumab and other anti-CD38 mAbs
- Survival improvement observed in Daudi, Ramos and Raji Xenograft models
- Worldwide license and commercial rights
- CID-103 is at IND/IMPD submission stage of development; phase I study targeted for first half 2020
ZEVALIN® and MARQIBO® Clinical Trial Application Approvals in China

- CD20-directed radiotherapeutic antibody indicated for treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s Lymphoma who achieve partial or complete response to first-line chemotherapy
- ZEVALIN® is approved and commercialized in the U.S. by our partner; CASI has exclusive greater China rights

- Novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor indicated for the treatment of (Phneg) acute lymphoblastic leukemia
- MARQIBO® is approved and commercialized in the US by our partner; CASI has exclusive greater China rights
Global Executive Team

Wei-Wu He, PhD
Chairman, CEO

Larry Zhang
President

Alexander Zukiwski, MD
CMO

George Chi, CPA
CFO

Thomas Zhang China
Commercial GM

Jim Goldschmidt, PhD
SVP, BD

Cissy Wang, JD
COO (US), General Counsel & Secretary

Cynthia Hu, JD
COO (US), General Counsel & Secretary

Cissy Wang, JD
COO (CASI Beijing)
Commercial Team with Hematologic Oncology Specialty and Track Record

- Senior commercial team (VPs, Dirs, DSMs), all with more than 10 years experiences at large international pharmaceutical companies

- **90%** of employees in commercial operations have prior experience in hematology oncology products

- **Successful launch of EVOMELA® in China** - Sales exceeded target forecast - Covered all of the major CBMTR (China bone marrow transplantation research group) centers in 26 provinces and 105 BMT Centers
R&D and Manufacturing Center in Wuxi, China

- State-of-the-art GMP facility currently in design and planning stage
- Completed land use acquisition for approximately 17.6 acres of land located in major biotech and pharmaceutical hub
- Over 100,000 square meters of building area
- Convenient transportation to 2 airports, high speed train station and highways
Business Development Partners

- **Spectrum Pharmaceuticals / Acrotech Biopharma, LLC**
  - Acquired exclusive China rights for three U.S. FDA-approved marketed products:
    - EVOMELA® (melphalan for injection), ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vincristine sulfate LIPOSOME injection)

- **Black Belt Therapeutics**
  - License agreement for exclusive worldwide rights to a novel anti-CD38 monoclonal antibody (CID-103)

- **Juventas Cell Therapy, Ltd.**
  - License agreement for exclusive worldwide license and commercialization rights to an autologous CD19 CAR-T cell therapy product (CNCT19)

- **Laurus Labs Limited**
  - Acquired U.S. FDA-approved ANDA for tenofovir disoproxil fumarate (TDF), indicated for the treatment of hepatitis B virus

- **Wuxi Huishan Economic Development Zone**
  - Agreements to build a state-of-the-art cGMP manufacturing site strategically located in the Jiangsu Province, China

- **Pharmathen**
  - Acquired China rights to EU approved product Octreotide (Long Acting Injectable (LAI) microsphere)

- **Sandoz, Inc.**
  - Acquired a portfolio of U.S. FDA-approved abbreviated new drug applications (ANDAs), and pipeline ANDAs
CASI Recap

- Launched EVOMELA® (melphalan for injection) for multiple myeloma, the only commercially available melphalan in China
- Robust pipeline in hematology oncology
  - CID-103 (potential best in class anti-CD38 mAb)
  - CNCT-19 (CD19 CAR-T Cell Therapy), Potential to be the first China-developed CD-19 CAR-T
  - ZEVALIN® (ibritumomab tiuxetan injection)
  - MARQibo® (vincristine LIPOSOME injection)
  - Octreotide (long acting injectable (LAI) microsphere)
- Led by an international executive team, with strong commercial and clinical/regulatory teams trained at large pharma, 100+ employees
- State-of-the-art GMP manufacturing facility currently in design stage; completed acquisition of land use rights for approximated 17.6 acres of land
- Strategic Business Development approach has enabled opportunistic pipeline expansion